Subscribe To
PALI / FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study
PALI News
By InvestorPlace
September 7, 2023
Why Is Palisade Bio (PALI) Stock Down 46% Today?
Palisade Bio (NASDAQ: PALI ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a share offering. Palisade Bio more_horizontal
By Zacks Investment Research
September 7, 2023
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies. more_horizontal
By Market Watch
September 6, 2023
Palisade Bio's stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies
Palisade Bio Inc.'s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant P more_horizontal
By Zacks Investment Research
April 6, 2023
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function more_horizontal
By InvestorPlace
March 31, 2023
Why Is Palisade Bio (PALI) Stock Up 36% Today?
Palisade Bio (NASDAQ: PALI ) stock is on the rise Friday after the biopharmaceutical company got an upgrade from an analyst. Maxim Group is behind tod more_horizontal
By Zacks Investment Research
March 29, 2023
What Makes Palisade Bio, Inc. (PALI) a New Buy Stock
Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Bu more_horizontal
By GlobeNewsWire
January 9, 2023
Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17 th at 3:00 PM ET more_horizontal
By Zacks Investment Research
November 23, 2022
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal more_horizontal